Pediatrics & Therapeutics
Open Access
ISSN: 2161-0665
+44 1478 350008
ISSN: 2161-0665
+44 1478 350008
Stephen Kirkby
Nationwide Children�s Hospital, USA
Keynote: Pediat Therapeut
Background: Despite resistant microbes, induction immunosuppression is used in patients with Cystic Fibrosis (CF) undergoing Lung Transplantation (LTx). Methods: To evaluate the effect of induction immunosuppression on survival, the United Network for Organ Sharing (UNOS) was queried restricting analysis to transplant patients 6-55 years old from 2001-2012, who received induction agents (INDUCED) or did not (NONE). Results: A total of 1,721 CF patients who underwent LTx were included in the analysis; of these 791 (46%) were INDUCED. Of the INDUCED patients, 65% received basiliximab, 10% alemtuzumab, and 25% thymoglobulin/anti-lymphocyte globulin/antithymocyte globulin. Mean age was 28 years (SD=9.7) and 28.5 (SD=9.5) for the INDUCED and NONE groups, respectively. The median survival in the INDUCED group was 93.8 months (95% CI: 73.8) compared to 61.8 months (95% CI: 55.8-73.8) for the NONE group (log rank p-value <0.001). Conclusions: Antibody-based induction immunosuppression had a strong overall survival benefit in CF patients undergoing LTx.
Stephen Kirkby, MD is the Clinical Director of the Lung and Heart-Lung Transplant Programs at Nationwide Children’s Hospital and an Assistant Clinical Professor of Internal Medicine and Pediatrics at The Ohio State University College of Medicine. He graduated from Penn State University College of Medicine. He completed his residency training in internal medicine and pediatrics at Ohio State University Medical Center and Nationwide Children’s Hospital. He continued to complete training fellowships in adult pulmonary/critical care medicine and pediatric pulmonary medicine. He is board certified in internal medicine, pediatrics, adult pulmonary medicine, critical care medicine and pediatric pulmonary medicine.